Checking the Safety and Effectiveness of IM-1617 for Advanced Cancer
NCT07578571 · RecruitingThis trial is studying a drug called IM-1617 for patients with advanced solid tumors. These tumors may have spread in the body or cannot be removed by surgery. The study has two parts. The first part will find the safest dose of IM-1617. The second part will look at how effective this dose is in treating these cancers.
Locations and contact
This trial is running at 1 location in the United States. It is currently recruiting.
United States1 location · 1 recruiting
- NEXT DallasIrving, TexasRecruiting
Who can join
Adults aged 18 and older can join the trial. Both men and women can participate. Participants should have certain types of solid tumors that cannot be treated with surgery. Some health conditions may prevent someone from joining. The trial team will check if you meet the eligibility criteria.
What happens during the trial
Participants will receive IM-1617 through an IV (a small tube in the vein). The study has two parts: the first part will test different doses to find the best one, while the second part will use that dose to see how well it treats the cancer. Everyone will receive IM-1617, and participants will not be placed in different groups by chance.
The trial team
Immunome, Inc. is leading this trial. They are responsible for conducting the study and ensuring everything runs smoothly.
Important dates
The trial started on May 21, 2026. It is expected to finish in January 2029. The trial is currently recruiting new participants.
Additional information
This is a Phase 1 trial, meaning it is focused on finding out how well the treatment works and how safe it is. The trial is regulated by the FDA, and they hope to enroll about 175 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →